Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Net Income towards Common Stockholders: 2021-2023

Historic Net Income towards Common Stockholders for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$25.6 million.

  • Cullinan Therapeutics' Net Income towards Common Stockholders rose 5.56% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 241.97%. This contributed to the annual value of -$167.6 million for FY2024, which is 8.04% down from last year.
  • Cullinan Therapeutics' Net Income towards Common Stockholders amounted to -$25.6 million in Q4 2023, which was up 34.76% from -$39.2 million recorded in Q3 2023.
  • Over the past 5 years, Cullinan Therapeutics' Net Income towards Common Stockholders peaked at $174.1 million during Q2 2022, and registered a low of -$58.1 million during Q1 2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$25.2 million (2022), whereas its average is -$9.4 million.
  • Over the last 5 years, Cullinan Therapeutics' Net Income towards Common Stockholders had its largest YoY gain of 1,158.85% in 2022, and its largest YoY loss of 1,006.27% in 2022.
  • Quarterly analysis of 3 years shows Cullinan Therapeutics' Net Income towards Common Stockholders stood at -$34.2 million in 2021, then rose by 20.87% to -$27.1 million in 2022, then rose by 5.56% to -$25.6 million in 2023.
  • Its Net Income towards Common Stockholders was -$25.6 million in Q4 2023, compared to -$39.2 million in Q3 2023 and -$32.2 million in Q2 2023.